Stay informed. See MDA updates on COVID-19

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Pfizer’s investigational gene therapy (PF-06939926) for Duchenne muscular dystrophy

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Saturday, August 1, 2020
Sponsor Information: 

This program is sponsored by Pfizer. This program is not sponsored, endorsed, or accredited by MDA.

Faculty

Beth Belluscio, MD-PhD
Pfizer Global Clinical Lead, Rare Neurological Disorders
Pfizer’s investigational gene therapy (PF-06939926) for Duchenne muscular dystrophy
Activity Overview: 

In this webinar, Beth Belluscio, Pfizer Global Clinical Lead for Rare Neurological Disorders, will discuss the Phase 3 study of PF-06939926, a gene therapy for Duchenne muscular dystrophy. Beth will answer questions about the study including aspects of the design and the criteria for enrollment.